| 产品详情 |
| Edit |   |
|---|
| Product Name | Bortezomib, deuterated |
|---|
| Description | Purity ~90%. Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Solubility: Chloroform, DMSO, Ethanol, Methanol Stability: Hygroscopic and moisture sensitive Atmosphere: Inert gas Method for determining Identity: Proton NMR and Mass Spectroscopic Analysis |
|---|
| Size | 1mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Bortezomib, deuterated (Velcade-deuterated, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid-deuterated) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | B2572-01 |
|---|
| Price | |
|---|
| Order / More Info | Bortezomib, deuterated from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|